These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 34415052)

  • 1. Bayesian adaptive trial design for a continuous biomarker with possibly nonlinear or nonmonotone prognostic or predictive effects.
    Liu Y; Kairalla JA; Renfro LA
    Biometrics; 2022 Dec; 78(4):1441-1453. PubMed ID: 34415052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bayesian adaptive patient enrollment restriction to identify a sensitive subpopulation using a continuous biomarker in a randomized phase 2 trial.
    Ohwada S; Morita S
    Pharm Stat; 2016 Sep; 15(5):420-9. PubMed ID: 27485377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do we need to adjust for interim analyses in a Bayesian adaptive trial design?
    Ryan EG; Brock K; Gates S; Slade D
    BMC Med Res Methodol; 2020 Jun; 20(1):150. PubMed ID: 32522284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adaptive randomized phase II design for biomarker threshold selection and independent evaluation.
    Renfro LA; Coughlin CM; Grothey AM; Sargent DJ
    Chin Clin Oncol; 2014 Mar; 3(1):. PubMed ID: 25485277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adaptive randomized phase II design for biomarker threshold selection and independent evaluation.
    Renfro LA; Coughlin CM; Grothey AM; Sargent DJ
    Chin Clin Oncol; 2014 Mar; 3(1):3. PubMed ID: 25842081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An adaptive biomarker basket design in phase II oncology trials.
    Liu S; Takeda K; Rong A
    Pharm Stat; 2023 Jan; 22(1):128-142. PubMed ID: 36163614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and analysis of biomarker-integrated clinical trials with adaptive threshold detection and flexible patient enrichment.
    Wang T; Wang X; George SL; Zhou H
    J Biopharm Stat; 2020 Nov; 30(6):1060-1076. PubMed ID: 33175640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ASIED: a Bayesian adaptive subgroup-identification enrichment design.
    Xu Y; Constantine F; Yuan Y; Pritchett YL
    J Biopharm Stat; 2020 Jul; 30(4):623-638. PubMed ID: 31782938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bayesian adaptive randomization designs for targeted agent development.
    Lee JJ; Xuemin Gu ; Suyu Liu
    Clin Trials; 2010 Oct; 7(5):584-96. PubMed ID: 20571130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bayesian group sequential enrichment designs based on adaptive regression of response and survival time on baseline biomarkers.
    Park Y; Liu S; Thall PF; Yuan Y
    Biometrics; 2022 Mar; 78(1):60-71. PubMed ID: 33438761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bayesian order constrained adaptive design for phase II clinical trials evaluating subgroup-specific treatment effect.
    Shan M; Guo B; Liu H; Li Q; Zang Y
    Stat Methods Med Res; 2023 May; 32(5):885-894. PubMed ID: 36919375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An adaptive design for updating the threshold value of a continuous biomarker.
    Spencer AV; Harbron C; Mander A; Wason J; Peers I
    Stat Med; 2016 Nov; 35(27):4909-4923. PubMed ID: 27417407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An extension of Bayesian predictive sample size selection designs for monitoring efficacy and safety.
    Teramukai S; Daimon T; Zohar S
    Stat Med; 2015 Sep; 34(22):3029-39. PubMed ID: 26038148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bayesian Two-stage Biomarker-based Adaptive Design for Targeted Therapy Development.
    Gu X; Chen N; Wei C; Liu S; Papadimitrakopoulou VA; Herbst RS; Lee JJ
    Stat Biosci; 2016 Jun; 8(1):99-128. PubMed ID: 27617040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Bayesian vs Frequentist Adaptive Trial Design in the Stroke Hyperglycemia Insulin Network Effort Trial.
    Broglio K; Meurer WJ; Durkalski V; Pauls Q; Connor J; Berry D; Lewis RJ; Johnston KC; Barsan WG
    JAMA Netw Open; 2022 May; 5(5):e2211616. PubMed ID: 35544137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel Bayesian adaptive design incorporating both primary and secondary endpoints for randomized IIB chemoprevention study of women at increased risk for breast cancer.
    Gajewski BJ; Kimler BF; Koestler DC; Mudaranthakam DP; Young K; Fabian CJ
    Trials; 2022 Dec; 23(1):981. PubMed ID: 36471449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using Bayesian adaptive designs to improve phase III trials: a respiratory care example.
    Ryan EG; Bruce J; Metcalfe AJ; Stallard N; Lamb SE; Viele K; Young D; Gates S
    BMC Med Res Methodol; 2019 May; 19(1):99. PubMed ID: 31088354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bayesian adaptive designs for multi-arm trials: an orthopaedic case study.
    Ryan EG; Lamb SE; Williamson E; Gates S
    Trials; 2020 Jan; 21(1):83. PubMed ID: 31937341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bayesian adaptive design for pediatric clinical trials incorporating a community of prior beliefs.
    Wang Y; Travis J; Gajewski B
    BMC Med Res Methodol; 2022 Apr; 22(1):118. PubMed ID: 35448963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Over-accrual in Bayesian adaptive trials with continuous futility stopping.
    Barrado LG; Burzykowski T
    Clin Trials; 2023 Jun; 20(3):252-260. PubMed ID: 36803007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.